At the news
? BULLISHIMPACT 6/10 6-K filed Jul 22, 2026 at 12:52 ET
GSK announced FDA approval of Jideytro (zidesamtinib) for previously treated ROS1-positive non-small cell lung cancer, ahead of the original PDUFA date of September 18, 2026. This is GSK's first approved lung cancer therapy and the first product from the recently completed Nuvalent acquisition, validating the deal's strategic rationale. The approval is based on the ARROS-1 phase I/II trial (ORR 44%, 12-month DOR rate 69%) and adds a targeted option for an oncogenic driver with ~50,000 annual diagnoses worldwide.
- FDA approved Jideytro (zidesamtinib) for ROS1-positive locally advanced or metastatic NSCLC after prior ROS1 TKI
- Approval granted ahead of original target action date (Sept 18, 2026) under Breakthrough Therapy and Orphan Drug designations
- ARROS-1 trial showed ORR 44% (95% CI 34-53%) in pre-treated population (n=117); 12-month DOR rate 69%
- Jideytro is GSK's first lung cancer approval and first asset from the recently completed Nuvalent acquisition
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access